Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 3(4)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01591863Phase 2Completed

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Role: lead

NCT01691248Phase 3Completed

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)

Role: lead

NCT01818141Phase 4Completed

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Role: collaborator

NCT01813500Completed

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Role: collaborator

NCT00468728Phase 3Completed

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Role: lead

NCT00314951Phase 3Completed

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Role: lead

NCT00097422Phase 2Completed

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Role: lead

NCT00448422Phase 3Completed

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

Role: lead

All 8 trials loaded